GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
January 08 2024 - 8:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced the
appointment of J. Marc Pipas, M.D., to serve as the Company’s
Executive Medical Director, Oncology.
Kelly McKee, M.D., MPH, GeoVax Chief Medical
Officer, commented, “Dr. Pipas’ addition to our team represents an
important step forward in the strengthening of GeoVax’s
organizational and operational resources to support advancement of
our principal oncology asset, Gedeptin®, through clinical
development and regulatory approval. He is also
well-positioned to guide the clinical development of GeoVax’s
broader immune-oncology portfolio. We are excited to leverage the
wealth of knowledge, expertise, and insights he will provide
relative to the clinical developments in support of our oncology
programs.”
“I am pleased to be joining the GeoVax team,” said
Dr. Pipas. “Oncologic research and development is my passion and I
look forward to engaging with our clinical researchers, regulatory
authorities, and the medical community at large, to advance
GeoVax’s mission.”
Dr. Pipas has extensive clinical, research, and
leadership expertise in oncology, built on a long and successful
academic career at Dartmouth-Hitchcock Medical Center/Norris Cotton
Cancer Center, an NCI Comprehensive Cancer Center. During his
academic career, Dr Pipas led the GI Clinical Oncology Group for
>10 years, served as Hematology/Oncology Fellowship Director,
was Medical Director for the Office of Clinical Research in the
Cancer Center, and served for more than a decade as a member of
Human Subject Protection and Data Monitoring Boards. Following his
academic career, he held positions of increasing responsibility in
the biopharma industry, guiding the development of several novel
oncology therapeutics through early- and late-stage clinical
trials.
Dr. Pipas received his Doctor of Medicine degree
from SUNY-HSC at Syracuse in 1989 and completed a residency in
Internal Medicine at the Medical University of South Carolina in
Charleston. Following this, he completed a fellowship in
Hematology/Oncology at Dartmouth-Hitchcock Medical Center in New
Hampshire and was then invited to become a faculty member at
Dartmouth Medical School where he achieved the rank of Full
Professor. He has 40 scientific papers and more than 60 abstracts
to his credit and has numerous nominations and awards for teaching
and humanism in medicine. Dr Pipas brings a deep understanding of
oncologic therapeutics and clinical trial management, as well as a
network of research contacts and leadership skills honed by many
years of experience.
About GeoVaxGeoVax Labs, Inc. is
a clinical-stage biotechnology company developing novel therapies
and vaccines for solid tumor cancers and many of the world’s most
threatening infectious diseases. The company’s lead program in
oncology is a novel oncolytic solid tumor gene-directed therapy,
Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for
advanced head and neck cancers. GeoVax’s lead infectious disease
candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in three Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a primary vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient, and as a booster vaccine in patients with chronic
lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding GeoVax’s business plans. The
words “believe,” “look forward to,” “may,” “estimate,” “continue,”
“anticipate,” “intend,” “should,” “plan,” “could,” “target,”
“potential,” “is likely,” “will,” “expect” and similar expressions,
as they relate to us, are intended to identify forward-looking
statements. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends that we believe may affect our financial
condition, results of operations, business strategy and financial
needs. Actual results may differ materially from those included in
these statements due to a variety of factors, including whether:
GeoVax is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Company
Contact: |
|
Investor
Relations Contact: |
|
Media
Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024